Biocon biosimilar plant criticized again by the FDA

Biocon research lab
Biocon research lab (Biocon)

The plant in India where Biocon makes the biosimilars it shares with Mylan was given a clean bill of health by the FDA last year—but not for long. The FDA posted a new Form 483 for the facility Tuesday following an inspection last month.

The most recent citation of the Bangalore plant includes only two observations, unlike in 2017 when a long list of problems led the FDA to delay approvals of the biosimilars that Mylan and Biocon were developing. The two notations, however, again spotlighted places where Biocon needs to tighten up its processes to prevent contamination of sterile drugs.

Biocon last month acknowledged the two observations and said they were part of a pre-approval inspection of a new injectables line at the plant. A separate inspection of a solid dose facility resulted in no observations. A Biocon spokesperson said in an email that the company has addressed the findings and responded to the regulator. She said Biocon remains committed to quality.    

Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

Specifically, the FDA faulted plant employees for not carefully sanitizing and inspecting its restricted-access barrier systems. The FDA didn’t like the way the plant was tracking rejected vials. Inspectors also said investigations into unexplained discrepancies didn’t always include all of the tests the FDA thought should be conducted.

When the plant ran into FDA concerns in 2017 during a preapproval inspection, Biocon initially downplayed what turned out to be an 8-page, 10-observation critique that found problems across the entire range of processes, including in aseptic processing and filling, environmental monitoring, data recording, cleaning procedures, and even in its processes for buying sterile gloves for employees. It took about 6 months for Biocon to get those issues resolved, and the efforts delayed approval of the partners’ Herceptin biosimilar by three months.

RELATED: FDA slams Biocon sterile plant where Herceptin biosimilar is to be produced

Last June, the Indian company reported to the stock exchange in India that the FDA had issued an Establishment Inspection Report for the plant, clearing that inspection. Last year, the Indian drugmaker also struck a partnership with Novartis to produce “next generation” biosimilars.

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.